<DOC>
	<DOCNO>NCT01756755</DOCNO>
	<brief_summary>Despite maintain adequate mean arterial pressure central venous oxygen saturation , mortality still high severe sepsis septic shock . Previous study demonstrate derangement microvascular flow play role sepsis-induced multiple organ dysfunction death . Lipopolysaccharide ( LPS ) endotoxin specific ligand Toll-like receptor 4 ( TLR4 ) , induce follow reaction include excessive immune inflammatory response , oxidative stress , capillary leakage , endothelial damage , impaired arteriolar venular vasoregulation , activation coagulation cascade 8 . Subsequently , reaction lead microcirculatory dysfunction . Polymyxin B adsorber hemoperfusion ( PMX ) prove reduce mortality severe sepsis septic shock . Since 1994 2007 , 60,000 patient receive treatment . In systematic review , result show PMX therapy associate significantly low mortality risk ( risk ratio , 0.53 ; 95 % CI , 0.43 0.65 ) . In prospective , multicenter , randomize control trial ( Early Use Polymyxin B Hemoperfusion Abdominal Sepsis [ EUPHAS ] ) , result show SOFA score improve polymyxin B group , 28-day mortality 32 % polymyxin B group 53 % conventional therapy group . The investigator hypothesize polymyxin B hemoperfusion decrease blood endotoxin level reduce endotoxin-related microcirculatory dysfunction . The purpose prospective , multicenter , randomize , control , open study investigate effect polymyxin B hemoperfusion sublingual microcirculation patient proven suspect gram-negative bacteria severe sepsis septic shock . The mean arterial pressure , dose vasopressor inotropics , SOFA score , PaO2/FiO2 ratio , 28-day mortality investigate .</brief_summary>
	<brief_title>Endotoxin Adsorber Hemoperfusion Microcirculation</brief_title>
	<detailed_description>Introduction Despite maintain adequate mean arterial pressure central venous oxygen saturation , mortality still high severe sepsis septic shock . Previous study demonstrate derangement microvascular flow play role sepsis-induced multiple organ dysfunction death . Because clinical significance microcirculatory dysfunction severe sepsis septic shock , recent advance image technology use investigate microcirculation . A sidestream dark-field ( SDF ) video microscope develop visualize microcirculation , measurement microvascular blood flow classification semi-quantitative . Previous study show full-field laser perfusion imager quantitatively measure change microcirculatory blood flow intensity . For clinical study , sublingual microcirculation easily investigate use SDF video microscope . Because lipopolysaccharide ( LPS ) endotoxin specific ligand Toll-like receptor 4 ( TLR4 ) , induce follow reaction include excessive immune inflammatory response , oxidative stress , capillary leakage , endothelial damage , impaired arteriolar venular vasoregulation , activation coagulation cascade . Subsequently , reaction lead microcirculatory dysfunction . Recently , TLR4 antagonist , eritoran tetrasodium ( E5564 ) , report inhibit LPS response without TLR4 agonistic activity animal well human , fail reduce mortality severe sepsis septic shock . Polymyxin B adsorber hemoperfusion ( PMX ) prove reduce mortality severe sepsis septic shock.Since 1994 2007 , 60,000 patient receive treatment . In systematic review , result show PMX therapy associate significantly low mortality risk ( risk ratio , 0.53 ; 95 % CI , 0.43 0.65 ) .21 In prospective , multicenter , randomize control trial ( Early Use Polymyxin B Hemoperfusion Abdominal Sepsis [ EUPHAS ] ) , result show SOFA score improve polymyxin B group conventional therapy group ( change SOFA , −3.4 v −0.1 ; P =0.001 ) , 28-day mortality 32 % polymyxin B group 53 % conventional therapy group ( unadjusted hazard ratio [ HR ] , 0.43 ; 95 % confidence interval [ CI ] , 0.20-0.94 ; adjust HR , 0.36 ; 95 % CI , 0.16-0.80 ) . Iba et al . reveal polymyxin B hemoperfusion maintain good microcirculation survival septic rat model . The investigator hypothesize polymyxin B hemoperfusion decrease blood endotoxin level reduce endotoxin-related microcirculatory dysfunction . The purpose prospective randomize control open study investigate effect polymyxin B hemoperfusion sublingual microcirculation patient clear suspect severe sepsis septic shock gram-negative bacteria . The serum level endotoxin , mean arterial pressure , dose vasopressor inotropics , SOFA score , PaO2/FiO2 ratio , 28-day mortality investigate . Methods This protocol review National Taiwan University Hospital Research Ethic Committee ( 201208067RIB ) . Patients meet inclusion criterion present exclusion criterion randomly assign one two group ( control group PMX-HP group ) . In control group , patient receive standard treatment sepsis accord practice guideline . In PMX-HP group , patient receive standard treatment sepsis polymyxin B hemoperfusion . The hemoperfusion perform intensive care unit within 24h diagnosis severe sepsis septic shock . The 1st PMX-HP ( day 0 ) run 2 hour . The 2nd PMX-HP must perform within 24 36 hour end 1st treatment , ideally 24 hour . The SDF video microscope ( MicroScan , Microvision Medical ) use investigate total small vessel ( le 20 μm ) density ( TSVD ) , microvascular blood flow classification small vessel , perfuse small vessel density ( PSVD ) , microvascular flow index ( MFI ) , heterogeneity index ( HI ) sublingual microcirculation . This device illuminate tissue polarize green light measure reflect light tissue surface . Both superficial capillary venule visualize scattered green light absorb haemoglobin red blood cell contain vessel . At time point ( 0h , 24h , 48h ) , five continuous image sequence ( 20 second ) digitally store , data best three image ( least , possible five ) average statistical calculation . The image analyse afterwards automate analysis software ( AVA 3.0 , Academic Medical Center , University Amsterdam , Amsterdam , The Netherlands ) . Total small vessel density automatically calculate software . A semi-quantitative method use classify microvascular blood flow small vessel follow : ( 0 ) absent ( flow fill microthrombosis ) , ( 1 ) intermittent flow ( absence flow least 50 % time ) , ( 2 ) sluggish flow , ( 3 ) continuous flow . ( Figure 1 ) Small vessel blood flow classification ( 2 ) ( 3 ) consider perfuse small vessel , perfuse small vessel density automatically calculate . To calculate MFI score , image divide four quadrant , ordinal scale ( 0 3 ) use assess blood flow quadrant . The MFI score represent averaged value four quadrant . The heterogeneity index calculate high MFI minus low MFI divide mean MFI across best three five image certain time point . Safety The blood pressure , body temperature , BUN , creatinine , ALT , AST , bilirubin ( total/direct ) , lactate , sodium , potassium , complete cell count monitor experiment . Adverse effect polymyxin B hemoperfusion ( bleeding , nephrotoxicity , neurotoxicity [ agitation , weakness , drowsy , ataxia , numbness , blur vision , paresthesia ] , thrombocytopenia , alter coagulation . ) monitor . Statistics According previous study , total small vessel density patient control group 20.0 mm/mm2 , 20 patient per group detect 12 % increase total small vessel density patient PMX-HP group α level 0.05 β level 0.8 . Data analyse use statistical software ( SPSS 20 ; IBM SPSS , Chicago , IL ) . Means certain time point two group compare use test . Means serial examination two group compare use repeat measurement analysis variance ( factor time group ) follow Tukey Dunnett 's T3 multiple comparison test . Data MFI express median ( interquartile range ) compare use Mann-Whitney analysis follow adjustment multiple comparison . A P value &lt; 0.05 consider indicate significant result .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<criteria>Patients include study meet follow criterion ( A+B+C ) : A . Patients follow condition : 1 . Abdominal cavity infection follow emergency surgery . 2 . Pneumonia , blood stream infection , urinary tract infection , infection , receive adequate treatment present Endotoxin Activity Assay &gt; 0.6 EAA unit . B. SIRS , define presence least 2 follow condition ( These criterion occur 12 hour 6 hour onset qualify first organ dysfunction : 1 . Fever hypothermia ( body temperature 38 ℃ 36 ℃ ) 2 . Tachycardia ( heart rate &gt; 90 bpm ) 3 . Tachypnea ( respiratory rate 20 breaths/min mechanical ventilation ) 4 . Leukocyte count 12,000 cells/mm3 , less 4,000 cells/mm3 , 10 % immature form ( band ) C. The presence least one symptom organ dysfunction shock : 1 . Cardiovascular system : SBP le 90 mm Hg , decrease SBP least 40 mm Hg baseline , MAP le 65 mm Hg , require treatment vasoactive medication dosage . 2 . Acute lung injury : PaO2 / FiO2 ratio le 300 ( ratio mm Hg ) 3 . Acute kidney injury : creatinine 2 mg/dL , increase creatinine 0.5 mg/dL , diuresis le 0.5 mL/kg/h 2 hour . 4 . Acute liver injury : Total bilirubin level 4 mg/dL 5 . Disseminated intravascular coagulation : platelet count le 100,000 cells/mm3 reduction 50 % baseline 6 . INR &gt; 1.5 aPTT &gt; 60 sec 7 . Altered mental status : GCS 13 9T endotracheal tube 8 . Lactic acidosis : Lactate level 2 mmol/L ( accompany pH &lt; 7.3 Base excess &lt; 5 mmol/L ) Patients exclude A. 20 year old old 99 year old B. suffer severe sepsis septic shock 24 hour C. pregnant D. treat another medicine device trial le 30 day prior admission trial E. receive organ transplantation le 1 year prior trial F. patient hemophilia G. allergic history polymyxin B , heparin , extracorporeal circulation H. terminally ill , example metastasis , life expectancy le 30 day ( certified attend physician ) I. diagnose HIV J. present uncontrolled bleed last 24 hour K. diagnose leukocytopenia ( leukocyte count le 500 cell/mm3 ) and/or thrombocytopenia ( platelet count le 50,000 cells/mm3 ) L. already receive blood cleaning treatment , CVVH , HD , HF , PE upon entry trial M. prior history severe chronic organ failure 1. chronic respiratory failure ( COPD last stage ) 2. chronic heart failure ( NYHA score = IV ) 3. brain death 4 . Chronic liver failure ( Child Pugh score : C ) N. evidence infection grampositive bacteria , fungal infection , mixed infection O. chosen palliative care sign Do Not Resuscitate sheet P. APACHE II score 30 present entry trial Q. nonnative speaker</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Sepsis</keyword>
</DOC>